Uehara H, Nakaizumi A, Baba M, Iishi H, Tatsuta M
Department of Gastrointestinal Oncology, Center for Adult Diseases, Osaka, Japan.
Br J Cancer. 1993 Jul;68(1):37-40. doi: 10.1038/bjc.1993.283.
The effect of verapamil on hepatocarcinogenesis induced by N-nitrosomorpholine (NNM) was investigated in male Sprague-Dawley rats. Rats were given drinking water containing NNM for 8 weeks and received i.p. injections of verapamil or vehicle every other day for 16 weeks from the start of the experiment. Pre-neoplastic and neoplastic lesions staining positive for gamma-glutamyl transpeptidase (GGT) or the placental type of glutathione-S-transferase (GST-P) were examined histochemically at week 16. Prolonged administration of verapamil resulted in a significant decrease in the number of GGT-positive and GST-P-positive lesions. The incidence and volume as a percentage of parenchyma of hepatocellular carcinomas were also significantly less in rats treated with verapamil than in controls. Administration of verapamil significantly decreased the labelling indices of pre-neoplastic lesions and adjacent liver. These findings indicate that verapamil inhibits hepatocarcinogenesis and that this may be related to its inhibitory effect on cell proliferation in neoplastic lesions and surrounding hepatocytes.
在雄性斯普拉格-道利大鼠中研究了维拉帕米对N-亚硝基吗啉(NNM)诱导的肝癌发生的影响。从实验开始,大鼠饮用含NNM的饮用水8周,并每隔一天腹腔注射维拉帕米或赋形剂,持续16周。在第16周时,通过组织化学方法检查γ-谷氨酰转肽酶(GGT)或胎盘型谷胱甘肽-S-转移酶(GST-P)染色阳性的癌前病变和肿瘤病变。维拉帕米的长期给药导致GGT阳性和GST-P阳性病变的数量显著减少。与对照组相比,用维拉帕米治疗的大鼠肝细胞癌的发生率和占实质的体积百分比也显著降低。维拉帕米的给药显著降低了癌前病变和相邻肝脏的标记指数。这些发现表明,维拉帕米抑制肝癌发生,这可能与其对肿瘤病变和周围肝细胞中细胞增殖的抑制作用有关。